A method of treating long-term unhealed erosion and ulceration of the cornea

 

(57) Abstract:

The invention relates to medicine and can be used to treat long-term unhealed erosion and ulceration of the cornea. Spend the coating defect of the cornea drug and subsequent exposure to the static magnetic field. As drug use deproteinizing hemodialysate from the blood of calves and/or deproteinizing gemoderiwat from the blood of calves 1-2 drops of the drug in the treated eyes within 6-14 days, and the effects of implementing permanent magnetic field with the induction of 120-160 MT daily for 2-8 min from 1 to 3 times a day. The number of sessions to choose from 12 to 28 during the course of treatment. The drug also use a mixture deproteinizing of hemodialysate from the blood of calves with 50 vol.% deproteinizing of hemoderivative from the blood of calves and deproteinizing gemoderiwat from the blood of calves, optionally containing low molecular weight peptides and derivatives of nucleic acids. The method allows to increase the effectiveness of the treatment is long not healing erosions and ulcers of the cornea. 2 C.p. f-crystals.

The invention relates to the field of medicine, ophthalmology, to methods for treating long what areas, includes coverage of the defect drug and subsequent exposure to magnetic field (RF patent 2164106, a 61 F 9/00, 2000).

However, the known method when its use does not completely eliminate Eviscerate the affected eye, does not provide a high saeplast erosion and ulceration of the cornea and does not preclude the re-emergence of a purulent process.

An object of the invention is to remedy these disadvantages and to provide a method for treatment of long-term unhealed erosion and ulceration of the cornea, allowing for its use to exclude Eviscerate the affected eye, to provide a high healing of erosion and ulceration of the cornea, and also to eliminate re-occurrence of purulent process.

The problem is solved in that a method of treatment of long-unhealed erosion and ulceration of the cornea, including the coating defect of the cornea drug with subsequent impacts on erosion and ulcer of the cornea constant magnetic field with an inductance of 120-160 MT, at the same time as drug use deproteinizing hemodialysate from the blood of calves and/or deproteinizing gemoderiwat from the slant of the drug mixture deproteinizing of hemodialysate from the blood of calves with about 50. % deproteinizing of hemoderivative from the blood of the calves. When this is used as a medicinal product deproteinizing gemoderiwat from the blood of calves, optionally containing low molecular weight peptides and derivatives of nucleic acids. The impact on erosion and ulcer of the cornea constant magnetic field exercise daily for 2-8 minutes 1 - 3 times a day, the number of selected sessions from 12 to 28 during the course of treatment.

Experimental studies of the proposed method of treatment is long not healing erosions and ulcers of the cornea in a clinical setting showed that using all of the distinctive features of the proposed technical solution achieved in the treatment of patients with the exception of Eviscerate the affected eye, ensuring high saeplast erosion and ulceration of the cornea, and also achieved the exception of the re-emergence of a purulent process.

Implementation of the proposed method for the treatment of long-term unhealed erosion and ulceration of the cornea is illustrated by the following clinical examples.

Example 1. Patient N. , 46 years old, was admitted to the Kaluga branch of IRTC "eye microsurgery" with the diagnosis of nonhealing erosion of the cornea of the right eye swollen epithelium at the edges.

The defect in the affected eye immediately before the session of magnetotherapy poured 2 drops deproteinizing of hemodialysate from the blood of calves and worked on a defect of the cornea constant magnetic field with an inductance of 160 MT daily for 6 days and 8 minutes 2 times a day. It was held 12 sessions of magnetotherapy.

Erosion was salpetersaure. At discharge visual acuity 0,63, three months later, visual acuity of 0.8.

Example 2. Patient A. , 67 years old, was admitted to the Kaluga branch of IRTC "eye microsurgery" with the diagnosis of Keratitis of the left eye with ulceration". Visual acuity of 0.2 on the cornea, respectively 6 o'clock rough infiltration up to 4 mm in diameter and with a defect of the epithelium in the center 2x2,5 mm

The defect in the affected eye immediately before the session of magnetotherapy poured 1 drop deproteinizing of hemoderivative from the blood of calves, optionally containing low molecular weight peptides and derivatives of nucleic acids, and worked on a defect of the cornea permanent magnetic field from the inductor 120 MT daily for 14 days for 2 minutes 2 times a day. It was conducted in 28 sessions of magnetotherapy.

In the process of healing of the epithelium saapi is and cornea, respectively 6 o'clock local persistent translucent haze 2 mm in diameter, which does not affect visual acuity.

Example 3. Patient P. , 58 years old, was admitted to the Kaluga branch of IRTC "eye microsurgery" with the diagnosis of Purulent corneal ulcer in the left eye". Visual acuity of 0.1, the cornea is edematous, respectively 3 hours of purulent corneal ulcer 2,5x2 mm saped edges and purulent infiltration around up to 5 mm in diameter. Fenomen "Tyndale" moisture in the front of the camera.

The defect in the affected eye immediately before the session of magnetotherapy poured 1 drop deproteinizing of hemodialysate from the blood of calves and 1 drop deproteinizing of hemoderivative from the blood of calves and worked on a defect of the cornea constant magnetic field with an inductance of 140 MT daily for 7 days for 5 minutes 3 times a day. It was held 21 sessions of magnetic therapy.

In the process of treating corneal edema was, purulent infiltration around the ulcer decreased, the cornea was shapetools. At discharge visual acuity of 0.5. Three months later, visual acuity 0,63, on the cornea, respectively, at 3 PM local persistent turbidity does not affect visual acuity.

Example 4. Patient B. , 69 years old, was admitted to the Kaluga branch of IRTC "eye microsurgery" diagnosis: "Neurotrophic turbidity 1x3 mm, the edge of the ulcer saped.

The defect in the affected eye immediately before the session of magnetotherapy poured 2 drops deproteinizing of hemodialysate from the blood of calves and worked on a defect of the cornea constant magnetic field with an inductance of 140 MT daily for 14 days, 8 minutes 1 time per day. It was held 14 sessions of magnetotherapy.

The ulcer was salpetersaure, infiltration resorbed. Visual acuity at discharge 0,63, three months later, visual acuity was 0.63.

1. A method of treating long-term unhealed erosion and ulceration of the cornea, including the coating defect of the cornea drug and subsequent exposure to the static magnetic field, characterized in that the quality of drug use deproteinizing hemodialysate from the blood of calves and/or deproteinizing gemoderiwat from the blood of calves 1-2 drops of the drug in the treated eyes within 6-14 days, and the effects of implementing permanent magnetic field with the induction of 120-160 MT daily for 2-8 minutes 1-3 times per day, the number of sessions to choose 12-28 for the course of treatment.

2. The method according to p. 1, characterized in that used as a medicinal product mixture S="ptx2">

3. The method according to any of the p. 1 or 2, characterized in that are used as drug deproteinizing gemoderiwat from the blood of calves, optionally containing low molecular weight peptides and derivatives of nucleic acids.

 

Same patents:

The invention relates to medicine, and is intended for the treatment of purulent wounds in the experiment
The invention relates to medicine, gastroenterology, Oncology
The invention relates to medicine and can be used to treat endourethral warts, localized in the posterior third of the hanging part of the urethra

The invention relates to medicine

The invention relates to the field of health and can be used for non-contact massage body tissues, prevention and treatment of diseases of the joints, skeletal system, muscles, blood vessels, etc
The invention relates to medicine, and is intended for the treatment of psoriatic arthritis

The invention relates to medicine, and is intended for the treatment of chronic adnexitis

The invention relates to medical equipment, namely, magnetic therapy, and is intended for the treatment of many diseases, including gastrointestinal - liver cirrhosis with portal hypertension and splenomegaly, chronic hepatitis, cholecystitis and cholelithiasis, pancreatitis, peptic ulcer and 12 duodenal ulcer; urological diseases, pyelonephritis, urolithiasis, the implementation of regeneration nonfunctioning kidneys, etc

The invention relates to medical equipment, namely, magnetic therapy, and can be used in the treatment of many diseases, including cirrhosis of the liver complicated forms in the course of regeneration of dysfunctional organs, the treatment of BPH, provides painless crushing and output concretions of various organs, treats mastitis and fibroadenoma of the mammary glands and uterine fibroids, atherosclerosis of vessels of lower extremities and many others without surgery and without the use of medication

The invention relates to medical equipment and can be used for magnetic therapy, and to examine the effect of variable low frequency of vortex magnetic fields on biological objects

The invention relates to medicine, namely to the means for treatment based on blood, and can be used in the treatment of patients with defects in epithelial tissues of different etiology

The invention relates to medicine, namely to create a restorative and tonic medicines
The invention relates to medicine, in particular to ophthalmology, and can be used for the treatment of patients with diabetic retinopathy
The invention relates to medicine, namely to intensive cardiology, and for the treatment of myocardial infarction

The invention relates to the field of veterinary medicine

The invention relates to medicine, more specifically to methods of preparative extracting protein fractions, in particular high-density lipoprotein (HDL), from plasma or serum, and can be used to determine the fractional-component composition (FCC) lipoprotein (LP) in the diagnosis of dyslipoproteinemia

The invention relates to medicine, namely to the field of immunotherapy, and relates to vaccines that are effective for the inhibition of multiple sclerosis, the method of inducing an immune response
The invention relates to medicine, namely to create medications for the treatment of burns

The invention relates to medicine and concerns immunostimulant, calling specific to the tumor cell immune response, and method of its production
The invention relates to medicine, namely to the technology of drugs

The way video // 2223552
The invention relates to tiflotechnika and is intended to represent video information, particularly color images, in a form comprehensible for a person with limited mobility impaired
Up!